The Food and Drug Administration will authorize the emergency use of the antiviral remdesivir on COVID-19 patients as soon as Wednesday, a senior administration official told The New York Times. Pharmaceutical company Gilead Sciences revealed promising study results involving remdesivir on Wednesday, but the FDA's reported move would still sidestep the usual testing required to authorize a drug's usage.
Gilead said Wednesday that its own trial, as well one overseen by the National Institute of Allergy and Infectious Diseases, met its goals. Of the study's 397 severe COVID-19 patients, at least 50 percent of patients treated with a 5-day dosage of remdesivir improved and more than half were discharged from the hospital within two weeks. The overall mortality rate of the study was 7 percent, and relatively few patients developed bad side effects. But the study wasn't evaluated against a control group, and it's unclear if those recoveries were natural or if remdesivir actually had something to do with them. Hard data from the study also hasn't been released yet.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Why some people remember dreams and others don'tUnder The Radar Age, attitude and weather all play a part in dream recall
-
The Week contest: Hotel sealPuzzles and Quizzes
-
New FBI Director Kash Patel could profit heavily from foreign interestsThe Explainer Patel holds more than $1 million in Chinese fashion company Shein
-
Ozempic can curb alcohol cravings, study findsSpeed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
-
New form of H5N1 bird flu found in US dairy cowsSpeed Read This new form of bird flu is different from the version that spread through herds in the last year
-
Microplastics accumulating in human brains, study findsSpeed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
-
FDA approves painkiller said to thwart addictionSpeed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
-
Study finds possible alternative abortion pillSpeed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
-
California declares bird flu emergencySpeed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
-
Bird flu one mutuation from human threat, study findsSpeed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
-
Dark chocolate tied to lower diabetes riskSpeed Read The findings were based on the diets of about 192,000 US adults over 34 years
